Home > Press > European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award
Abstract:
The goal of the Award is to recognize innovative nanomedicine-based solutions that could help physicians change the way diseases are treated and diagnosed, bringing significant benefits to patients.
The Award is open to companies, academic and private researchers across the globe. Nominated projects should represent new diagnostic and therapeutic approaches that address unmet medical needs, are not feasible without nanotechnology, are clearly distinct from standard approaches and have an explicit defined potential market.
Projects will be evaluated on the basis of being either a concept or a preclinical or clinical application in nanotherapeutics, diagnostic or regenerative medicine. Applications will be reviewed and assessed by a panel of highly-qualified pharma industry specialists with experience in R&D and commercial roles: Laurent Levy, Nanobiotix; Neil Desai, Celgene; Mike Eaton, consultant; Patrick Tricoli, Sanofi; Karen Zinkevich-Peotti, Ipsen and Thorsten Melcher, Johnson & Johnson Innovation.
The Award is supported by the EBD Group, the leading partnering firm for the global life science industry, and Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The presentation of the Award will take place during the Nanomedicine Panel Discussion at BIO-Europe 2013 in Vienna, Austria, on 4th November 2013.
The winners will receive media coverage across Europe and gain visibility to EU decision makers from biotechnology, pharma, academia and finance. Winners will also benefit from a full registration (including partnering) for BIO-Europe 2013 and a 5 minute presentation slot at the Nanomedicine Panel Discussion during the event. In addition, the winning project will also be granted a 15 minute presentation slot during the CLINAM conference 2014 in Basel, Switzerland, along with 1 year's free ETPN membership and two days consultation by the members of the ETPN Translational Advisory Board.
Entries for nominations for the Award will be open from 6th June to 7th September 2013. The application form is available online: www.nanomedicine-award.com.
####
About VDI/VDE-Innovation + Technik GmbH
For High Tech to become a success story, VDI/VDE Innovation + Technik GmbH (VDI/VDE-IT) has been working hard for more than 25 years to be a reliable partner of industry and research and of the political community. With our fields of activity - Research Funding, Technology Politics and Innovation Management – we are covering the entire spectrum of the innovation process, from research through application all the way to the introduction and use of new technologies.
Our customers at home and abroad wish to implement innovations in the high-tech sector. Bringing our knowledge and experience to bear in important key technologies such as microsystems engineering, bio and nano technology and the multimedia, we assist our clients in translating their ideas into action, helping them to make their high-tech projects a success. With this objective in mind, our multidisciplinary team of over 100 experts in the natural and social sciences, engineers, and economists are continuously developing new ideas and methods, tailor-made to the personal needs of our customers.
VDI/VDE Innovation + Technik GmbH is a society of VDI GmbH and of VDE (Association for Electrical, Electronic & Information Technologies).
About ETP Nanomedicine - www.etp‐nanomedicine.eu
The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
About BIOEUROPE 2013 - www.ebdgroup.com/bioeurope
The 19th annual BIO-Europe event will be the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance, representing upwards of 1,700 companies from over 50 countries, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place November 4–6, 2013 in Vienna, Austria.
Follow BIO-Europe 2013 on Twitter: twitter.com/ebdgroup (hashtag: #BEU13)
For more information, please click here
Contacts:
Wiebke Ehret
+49 30 310078-125
Copyright © AlphaGalileo
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Atomic force microscopy in 3D July 5th, 2024
Aston University researcher receives £1 million grant to revolutionize miniature optical devices May 17th, 2024
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||